The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography

https://doi.org/10.1016/0922-4106(92)90121-BGet rights and content

Abstract

Since [3H]cmonapride ([3H]YM-0915-2), a benzamide neuroleptic, consistently detects more dopamine D2 receptors than [3H]spiperone in the same tissue, we tested whether this property was inherent in the cloned dopamine D2 receptor. We found that the density of dopamine D2 receptors labelled by [3H]cmonapride was 15-fold to 2-fold (mean of 1.8-fold) higher than the density of dopamine D2 receptors labelled by [3H]spiperone in cells expressing cloned dopamine D2 receptors (either the short form (from rat) or the long form (from human)), matching similar findings in anterior pituitary tissue (rat or pig) or in post-mortem human caudate nucleus tissue. The situation was similar for another benzamide, [3H]raclopride, which revealed 1.3-fold to 1.8-fold (mean of 1.5-fold) more binding sites than that for [3H]spiperone in cell membranes containing cloned dopamine D2 receptors. The apparently different dopamine D2 receptor densities revealed by these two types of 3H-ligands (i.e. [3H]spiperone and the [3H]benzamides), therefore, arise from an inherent property of the dopamine D2 receptor protein. These findings for the cloned dopamine D2 receptor, therefore, partly explain the higher dopamine D2 receptor density measured in human brain (by positron emission tomography) when using radioactive raclopride compared to results using radioactive methylspiperone. Hence, the apparent density of dopamine D2 receptors measured by radioactive raclopride may be lower or higher than that revealed by radioactive spiperone or methylspiperone, depending on the magnitude of endogenous dopamine (which inhibits the binding of radioactive raclopride) and the inherent property of dopamine D2 receptor proteins to exhibit more binding sites (D2 monomers, possibly) for radioactive benzamides than for radioactive spiperone or methylspiperone (D2 dimers, possibly).

References (39)

  • B.C. Cunningham et al.

    Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule

    Science

    (1991)
  • S.G. Dahl et al.

    Molecular dynamics of dopamine at the D2 receptor

  • L. Farde et al.

    D2 dopamine receptors in neuroleptic-naive schizophrenic patients: a positron emission tomography study with [11C]raclopride

    Arch. Gen. Psychiatry

    (1990)
  • D.K. Grandy et al.

    Cloning of the cDNA and gene for a human D2 dopamine receptor

  • K. Hatano et al.

    D2-Dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2

    J. Nucl. Med.

    (1989)
  • J. Hatazawa et al.

    Measurement of D2 dopamine receptor-specific carbon-11-YM-09151-2 binding in the canine brain by PET: importance of partial volume correction

    J. Nucl. Med.

    (1991)
  • M.F. Hibert et al.

    Three-dimensional models of neurotransmitter G-binding protein-coupled receptors

    Mol. Pharmacol.

    (1991)
  • S. Higuchi et al.

    Comparative pharmacokinetics of a new benzamide neuroleptic drug in rats, dogs and monkeys using a stable isotope technique

    Xenobiotica

    (1986)
  • O. Inoue et al.

    Difference in in vivo receptor binding between [3H]N-methylspiperone and [3H]raclopride in reserpine-treated mouse brain

    J. Neural Trans.

    (1991)
  • Cited by (66)

    • Schizophrenia thalamus imaging: Low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and fewer presynaptic terminals

      2013, Psychiatry Research - Neuroimaging
      Citation Excerpt :

      A third possible explanation is that the spiperone ligands and the benzamide ligands bind to different aspects of the D2 receptors. For example, the spiperone ligands bind to monomers of D2, while the benzamides bind to dimers or multimers of D2 receptors (Seeman et al., 1992; Zawarynski et al., 1998). For example, nemonapride (also known as emonapride), as well as raclopride, are benzamide antipsychotic drugs that consistently detect 50% more dopamine D2 receptors than spiperone in the same tissue, including the cloned D2 receptor (Seeman et al., 1992).

    • Antagonist-radioligand binding to D<inf>2L</inf>-receptors in intact cells

      2008, Biochemical Pharmacology
      Citation Excerpt :

      That binding of [3H]-spiperone to intracellular D2L-receptors might be reflected as non-specific binding is unlikely since, in the present study, it was similar to the total (and non-displaceable) [3H]-spiperone binding in the parent CHO-AEQ cells. Studies with cell membrane preparations yield distinct D2-receptor binding capacities when comparing radiolabelled benzamides and butyrophenones [24,28,37,38]. However, this could reflect the ionic composition of the incubation medium.

    • Dopamine D<inf>2</inf> receptor dimer formation. Evidence from ligand binding

      2001, Journal of Biological Chemistry
      Citation Excerpt :

      The model may also explain some other phenomena that have been observed for the D2 dopamine receptor such as the observation of two rates of radioligand dissociation (31, 45), the complex pH dependence of the binding of some ligands (46), and the pseudocompetition of amiloride analogues versus [3H]spiperone binding with Hill coefficients close to 2 (31, 45). The dimeric model may be an oversimplification, since there are reports that other radioligands (e.g. [3H]nemonapride) are able to label more receptors than [3H]spiperone (19,21), suggesting that higher order species than dimers may exist. The present data are, however, consistent with homodimers.

    View all citing articles on Scopus
    View full text